Table 1.
Comparison of clinical characteristics between groups.
| Clinical Characteristic |
Microparticles group
n = 40 (%) |
Placebo group
n = 39 (%) |
p |
| Sex | |||
| Male | 16 (40.00) | 23 (58.97) | 0.0917 |
| Female | 24 (60.00) | 16 (41.03) | |
| Age (years) | |||
| Median | 53.50 | 59.00 | |
| <65 | 33 (82.50) | 31 (79.49) | 0.7328 |
| ≥65 | 7 (17.50) | 8 (20.51) | |
| Smoking status | |||
| Never smoker | 13 (32.50) | 18 (46.15) | 0.2093 |
| Ever smoker | 26 (65.00) | 20 (51.28) | |
| NA | 1 (2.50) | 1 (2.57) | |
| ECOG performance status | |||
| 1 | 34 (85.00) | 34 (87.18) | 0.7797 |
| 2 | 6 (15.00) | 5 (12.82) | |
| Histological type | |||
| Adenocarcinoma | 40 (100.00) | 39 (100.00) | – |
| Others | 0 (0.00) | 0 (0.00) | |
| Baseline volume of pleural effusion | |||
| <1000ml | 29 (72.50) | 22 (56.41) | 0.1350 |
| ≥1000ml | 11 (27.50) | 17 (43.59) | |
| Metastatic sites | |||
| Brain | 8 (20.00) | 8 (20.51) | |
| Bone | 18 (45.00) | 12 (30.77) | 0.5421 |
| Others | 6 (15.00) | 8 (20.51) | |
| T stage | |||
| T1 | 4 (10.00) | 4 (10.26) | 0.9532* |
| T2 | 9 (22.50) | 8 (20.51) | |
| T3 | 5 (12.50) | 3 (7.69) | |
| T4 | 17 (42.50) | 17 (43.59) | |
| Tx | 5 (12.50) | 7 (17.95) | |
| N stage | |||
| N0 | 0 (0.00) | 2 (5.13) | 0.0951* |
| N1 | 5 (12.50) | 1 (2.56) | |
| N2 | 18 (45.00) | 18 (46.15) | |
| N3 | 15 (37.50) | 11 (28.21) | |
| Nx | 2 (5.00) | 7 (17.95) | |
| EGFR mutation | |||
| Yes | 15 (37.50) | 15 (38.46) | 0.5275 |
| No | 18 (45.00) | 13 (33.33) | |
| Not-test | 7 (17.50) | 11 (28.21) | |
| ALK status | |||
| Positive | 1 (2.50) | 2 (5.13) | 0.7937 |
| Negative | 19 (47.50) | 13 (33.33) | |
| Not-test | 20 (50.00) | 24 (61.54) | |
*Fisher’s exact test.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NA, not available.